Clinical Trial Update: Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating Pyronaridine-artesunate with low-dose primaquine to prevent transmission of Plasmodium falciparum malaria (Phase 2 and Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• Primaquine (primaquine)
• Pyronaridine-artesunate (pyronaridine/artesunate)

Snippet

Sponsor: London School of Hygiene and Tropical Medicine | Conditions: Malaria,Falciparum | Phase 2, Phase 3 | Status: COMPLETED